Literature DB >> 22102186

Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder.

Emmanuel J Favaloro1.   

Abstract

von Willebrand disease (VWD) is the most common inherited bleeding disorder and arises from deficiencies and/or defects in the plasma protein von Willebrand factor (VWF). The current report overviews the diagnosis and management of VWD as reflected by differential processes applied within centers around the world. The prevalence of VWD, as well as the frequency of different VWD types, is also reported. VWD prevalence data varies according to methodology used, with epidemiological/population screening estimates approximating 1% of the population (or 10,000 cases per million population), several orders of magnitude higher than estimates from bleeding disorders registry data or regional/center analysis (which instead range from <1 to ~450 cases per million population). Frequency of different VWD types also varies according to source and analysis, with type 1 VWD identified as the clear dominant type in most developed countries (ranging from 40% to 90% of all VWD cases), whereas type 3 VWD predominates in developing countries such as India and Iran. The frequency of qualitative (i.e., type 2) VWD also varies considerably among different reports, ranging from 3% to >50% of all VWD cases, as does the frequency of specific qualitative VWD types (i.e., 2A, 2B, 2M, and 2N). Although type 2A VWD is considered the most common form of type 2 VWD, in some reports workers consider type 2M VWD to be as, or more, common. Although not considered to be a "true" VWD, given its platelet origin, platelet-type VWD is only rarely identified. Finally, management of VWD also differs according to geographic region. Most developed countries use standard therapy, employing desmopressin (DDAVP) wherever possible, factor concentrate in other situations, and antifibrinolytic therapy as required. In contrast, the relative high cost and unavailability of factor concentrates in developing countries, and sometimes the unavailability of DDAVP, requires different management strategies to be applied. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102186     DOI: 10.1055/s-0031-1281028

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  13 in total

1.  An international survey to inform priorities for new guidelines on von Willebrand disease.

Authors:  Mohamad A Kalot; Mohammed Al-Khatib; Nathan T Connell; Veronica Flood; Romina Brignardello-Petersen; Paula James; Reem A Mustafa
Journal:  Haemophilia       Date:  2019-11-26       Impact factor: 4.287

2.  Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use.

Authors:  Marika Pikta; Timea Szanto; Margus Viigimaa; Sandra Lejniece; Dārta Balode; Kadri Saks; Valdas Banys
Journal:  J Med Biochem       Date:  2021-03-12       Impact factor: 3.402

Review 3.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

Review 4.  Rare forms of von Willebrand disease.

Authors:  Emmanuel J Favaloro
Journal:  Ann Transl Med       Date:  2018-09

5.  Von Willebrand disease type 2M: Correlation between genotype and phenotype.

Authors:  Dominique P M S M Maas; Ferdows Atiq; Nicole M A Blijlevens; Paul P T Brons; Sandy Krouwel; Britta A P Laros-van Gorkom; Frank W G Leebeek; Laurens Nieuwenhuizen; Selene C M Schoormans; Annet Simons; Daniëlle Meijer; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2021-11-21       Impact factor: 16.036

Review 6.  Why Do Patients Bleed?

Authors:  Jennifer Curnow; Leonardo Pasalic; Emmanuel J Favaloro
Journal:  Surg J (N Y)       Date:  2016-02-24

Review 7.  Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Clin Med       Date:  2017-04-10       Impact factor: 4.241

8.  Desmopressin acetate use in von Willebrand's disease: a survey on current practices in Brazil.

Authors:  Maria Sueli da Silva Namen Lopes; Suely Meireles Rezende
Journal:  Hematol Transfus Cell Ther       Date:  2020-01-30

9.  Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity.

Authors:  Y Ni; J Nesrallah; M Agnew; F J Geske; E J Favaloro
Journal:  Int J Lab Hematol       Date:  2012-10-29       Impact factor: 2.877

10.  Two cases of von Willebrand disease type 3 in consanguineous Chinese families.

Authors:  Xiong Wang; Ning Tang; Yanjun Lu; Qun Hu; Dengju Li
Journal:  Mol Genet Genomic Med       Date:  2019-12-02       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.